Prana launches Phase II study of Alzheimer's drug

03/6/2012 | ProactiveInvestors.co.au (Australia)

Prana Biotechnology has started with the first patient in a 12-month Phase II trial that will monitor levels of amyloid in the brain and assess cognitive and functional abilities in participants treated with PBT2, the company's investigational drug for Alzheimer's disease. Study participants will undergo PiB-PET imaging prior to treatment to determine starting amyloid levels.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX